EDSA | Edesa Biotech, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	4.02 - 4.40
52 Week Range	2.4600 - 8.33
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	12,486
Average Volume	8,188
Shares Outstanding	3,247,390
Market Cap	13,679,306
Sector	Healthcare
Industry	Biotechnology
IPO Date	2010-06-21

Valuation
Profitability
Growth
Health
P/E Ratio	-0.21
Forward P/E Ratio	N/A
EPS	-19.78
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	16
Country	Canada
Website	EDSA

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

EDSA's peers: SABSW, SNTI, CING, BLCM, HILS, NRBO, INDP, KTTA, QNRX, LIXT, CMRA, SABS, PCSA, FRTX, THRD, ADTX, PALI, PSTV, REVB, NTRB, LGVN, RNXT, VRAX

*Chart delayed

Analyzing fundamentals for EDSA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see EDSA Fundamentals page.

Watching at EDSA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on EDSA Technicals page.